Literature DB >> 29128902

Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy.

Phillip F Giannopoulos1, Domenico Praticò2.   

Abstract

Brain accumulation of increasing amount of phosphorylated microtubule associated tau protein is one the major hallmark lesions of Alzheimer's disease (AD) and related tauopathies. Consistent evidence from clinical and animal studies has shown that neuroinflammation characterizes these diseases. The 5-lipoxygenase (5LO) is an enzyme protein whose metabolic products are lipids with potent inflammatory actions. Previously, we showed that blockade of 5LO activation ameliorates the phenotype of the htau transgenic mice. Here, by employing a vector system to overexpress 5LO in the brain of the same mouse model, we investigated its role and contribution to their behavioral deficits and development of tau neuropathology. Compared with controls, 5LO gene targeted mice manifested significant impairments in their memory and learning ability. On the other hand, brain tissues of the same mice had higher 5LO protein level and activity which resulted in intense neuroinflammation and synaptic pathology. Further, the same mice had a significant elevation of tau phosphorylation, which associated with the activation of the cdk5 kinase and an accumulation of insoluble tau. The functional involvement of this kinase in the 5LO-dependent tau phosphorylation was confirmed in neuronal cells. Taken together, our findings demonstrate that neuronal 5LO is directly involved in tau phosphorylation and tau neuropathology, and for this reason, it should be considered a good therapeutic target for tauopathies.

Entities:  

Keywords:  5-Lipoxygenase; Alzheimer’s disease; Neuroinflammation; Tau protein; Tauopathy; Transgenic mice

Mesh:

Substances:

Year:  2017        PMID: 29128902     DOI: 10.1007/s12035-017-0817-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  25 in total

Review 1.  Spatial memory: Theoretical basis and comparative review on experimental methods in rodents.

Authors:  Carrillo-Mora Paul; Giordano Magda; Santamaría Abel
Journal:  Behav Brain Res       Date:  2009-05-23       Impact factor: 3.332

Review 2.  Putative role of neuronal 5-lipoxygenase in an aging brain.

Authors:  H Manev; T Uz; K Sugaya; T Qu
Journal:  FASEB J       Date:  2000-07       Impact factor: 5.191

3.  The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old.

Authors:  Cinzia M Chinnici; Yuemang Yao; Domenico Praticò
Journal:  Neurobiol Aging       Date:  2006-08-22       Impact factor: 4.673

4.  Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration.

Authors:  K Ishizawa; D W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2001-06       Impact factor: 3.685

5.  Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase.

Authors:  Jin Chu; Domenico Praticò
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

Review 6.  Novel lipid signaling pathways in Alzheimer's disease pathogenesis.

Authors:  Phillip F Giannopoulos; Yash B Joshi; Domenico Praticò
Journal:  Biochem Pharmacol       Date:  2013-11-21       Impact factor: 5.858

Review 7.  The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target.

Authors:  Jin Chu; Domenico Praticò
Journal:  Brain Res Bull       Date:  2016-03-19       Impact factor: 4.077

Review 8.  An updated assessment of microglia depletion: current concepts and future directions.

Authors:  Jinming Han; Robert A Harris; Xing-Mei Zhang
Journal:  Mol Brain       Date:  2017-06-19       Impact factor: 4.041

9.  Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease.

Authors:  P F Giannopoulos; J Chu; Y B Joshi; M Sperow; J-G Li; L G Kirby; D Praticò
Journal:  Mol Psychiatry       Date:  2013-03-12       Impact factor: 13.437

10.  Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.

Authors:  Ksenia Kurbatskaya; Emma C Phillips; Cara L Croft; Giacomo Dentoni; Martina M Hughes; Matthew A Wade; Safa Al-Sarraj; Claire Troakes; Michael J O'Neill; Beatriz G Perez-Nievas; Diane P Hanger; Wendy Noble
Journal:  Acta Neuropathol Commun       Date:  2016-03-31       Impact factor: 7.801

View more
  6 in total

Review 1.  Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 2.  Leukotriene biosynthetic enzymes as therapeutic targets.

Authors:  Jesper Z Haeggström
Journal:  J Clin Invest       Date:  2018-07-02       Impact factor: 14.808

Review 3.  Intersection of pathological tau and microglia at the synapse.

Authors:  Thomas Vogels; Adriana-Natalia Murgoci; Tomáš Hromádka
Journal:  Acta Neuropathol Commun       Date:  2019-07-05       Impact factor: 7.801

Review 4.  Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death.

Authors:  Qian-Yi Sun; Hong-Hao Zhou; Xiao-Yuan Mao
Journal:  Oxid Med Cell Longev       Date:  2019-11-29       Impact factor: 6.543

5.  Critical involvement of lysyl oxidase in seizure-induced neuronal damage through ERK-Alox5-dependent ferroptosis and its therapeutic implications.

Authors:  Xiaoyuan Mao; Xuan Wang; Mingzhu Jin; Qin Li; Jining Jia; Menghuan Li; Honghao Zhou; Zhaoqian Liu; Weilin Jin; Yanli Zhao; Zhong Luo
Journal:  Acta Pharm Sin B       Date:  2022-05-10       Impact factor: 14.903

6.  The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.

Authors:  Johanna Michael; Julia Zirknitzer; Michael Stefan Unger; Rodolphe Poupardin; Tanja Rieß; Nadine Paiement; Horst Zerbe; Birgit Hutter-Paier; Herbert Reitsamer; Ludwig Aigner
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.